Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 18
---
ected a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such
that one Depositary Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

On December 16, 2022,
we sold to an institutional investor 492,400 Ordinary Shares represented by 4 Depositary Shares in a registered direct offering at $80,000.00
per Depositary Share, resulting in gross proceeds of approximately $0.4 million.

On February 15, 2023,
we completed the closing of a private placement, or the February Private Placement, pursuant to which we sold to certain institutional
investors (1) 3,250,000 Ordinary Shares represented by 32 Depositary Shares at $46,400.00 per Depositary Share, (2) 12,931,020 Ordinary
Shares represented by 129 Depositary Shares, issuable upon the exercise of Series A warrants, or Series A Warrants, issued in the February
Private Placement at an exercise price of $53,600.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 193 Depositary Shares,
issuable upon the exercise of Series B warrants, or Series B Warrants, issued in the February Private Placement at an exercise price
of $55,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 621 Depositary Shares, issuable upon the exercise of pre-funded
warrants issued in the February Private Placement at an exercise price of $8.00 per warrant, for aggregate gross proceeds of approximately
$6.0 million. We also issued unregistered warrants to the placement agent in the offering, or the February Placement Agent Warrants,
to purchase a total of 500,000 Ordinary Shares represented by five Depositary Shares to the placement agent at an exercise price of $58,000.00
per warrant, and Series A Warrants to purchase 625,000 ordinary shares represented by six Depositary Shares at an exercise price
of $53,600.00 per warrant to an investor pursuant to a waiver.

On March 27, 2023, following
shareholder approval, we effected a one-for-20 reverse stock split of our ordinary shares, and our ordinary shares began trading on AIM
on a split-adjusted basis as of such date. No fractional shares were issued in connection with the